Advanced search
Publication Cover
HIV Clinical Trials Volume 10, 2009 - Issue 5
Submit an article Journal homepage
31
Views
1
CrossRef citations to date
0
Altmetric
Brief reports

Viral Load Decay in Antiretroviral-Naïve Patients Receiving Once-Daily Tenofovir and Emtricitabine plus Twice-Daily Nevirapine

Anthony AmorosoInstitute of Human Virology University of Maryland School of Medicine, Baltimore, Maryland, USA
,
Bruce L. GilliamInstitute of Human Virology University of Maryland School of Medicine, Baltimore, Maryland, USACorrespondence[email protected]
,
Rohit TalwaniInstitute of Human Virology University of Maryland School of Medicine, Baltimore, Maryland, USA
,
Colleen BoyceInstitute of Human Virology University of Maryland School of Medicine, Baltimore, Maryland, USA
,
Robert R. RedfieldInstitute of Human Virology University of Maryland School of Medicine, Baltimore, Maryland, USA
&
Charles E. DavisInstitute of Human Virology University of Maryland School of Medicine, Baltimore, Maryland, USA
Pages 320-323 | Published online: 06 Jan 2015

REFERENCES

  • Robertson C, Berry A, Mahungu J, et al. Truvada (TDF + FTC) or TDF + 3TC and once daily nevirapine: individualiz-ing patient care with TDM and early intervention is associ-ated with optimal outcomes. Presented at: 11th European AIDS Conference; October 24–27, 2007; Madrid, Spain. Abstract P4.2/02.
  • Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New Engl J Med. 2006;354:251–260.
  • Smith KY, Weinberg WG, Dejesus E, et al; for the ALERT (COL103952) Study Team. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5:5.
  • Molina JM, Podsadecki TJ, Johnson MA, et al. A lopi-navir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23:1505–1514.
  • Rey D, Hoen B, Chavanet P, et al. High rate of early virologic failure with the once daily tenofovir/lamivudine/ nevirapine combination in naive HIV-infected patients. J Antimicrob Chemother 2009;63:380–388.
  • Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis. 2008;46:1127–1129.
  • Clotet B. Once daily dosing of nevirapine in HAART. J Antimicrob Chemother 2008;61:13–16.
  • Davis C, Gilliam B, Amoroso A, et al. Lack of pharma-cokinetic interaction of tenofovir (TDF) and emtricitabine (FTC) on nevirapine (NVP). Presented at: 11th European AIDS Conference; October 24–27, 2007; Madrid, Spain. Abstract P4.1/03.
  • Boehringer Ingelheim Pharmaceuticals. Nevirapine vs. ate-zanavir boosted with ritonavir on a background of Truvada in HIV infected naive patients (NEwArT). ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00552240. Published September 28, 2007. Updated February 5,2009. Accessed February 14, 2009.
  • Boehringer Ingelheim Pharmaceuticals. Observational non-interventional study with viramune in combination with Truvada in HIV-infected patients. ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00543803. Published October 8, 2007. Updated January 28,2009. Accessed February 14, 2009.
  • Calmy A, Nguyen A, Lange J, et al. Nevirapine adminis-tered once daily is as efficient as a twice-daily dosing. A collaborative cohort study. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA. Abstract 786.
  • Boehringer Ingelheim Pharmaceuticals. VERxVE study on efficacy and safety of nevirapine XR in comparison to nevirapine IR with Truvada in naive HIV+ patients. Clinical-Trials.gov Web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00561925. Published November 20, 2007. Updated February 10,2009. Accessed February 14, 2009.
  • Boehringer Ingelheim Pharmaceuticals. Nevirapine or atazanavir/ritonavir given with emtricitabine/tenofo-vir DF in HIV-1-infected treatment naive adults (ARTEN) ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00389207. Published October 17, 2006. Updated January 27, 2009. Accessed February 14, 2009.
  • Amoroso A, Sheneberger R, Edozien A, et al. ART-associated toxicities leading to a switch in medication: experience in Uganda, Kenya, and Zambia. Presented at: 14th Con-ference on Retroviruses and Opportunistic Infections; February 25–28, 2007; Los Angeles, CA. Abstract 789.
  • Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2)191–201.
  • Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1 -infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1–139. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdo-lescentGL.pdf. Accessed Dec. 23, 2008 [pp. 29, 38].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.